First Light Asset Management LLC Has $37.06 Million Position in Health Catalyst, Inc. (NASDAQ:HCAT)

First Light Asset Management LLC grew its holdings in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 22.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,241,121 shares of the company's stock after purchasing an additional 944,631 shares during the period. Health Catalyst comprises approximately 3.5% of First Light Asset Management LLC's investment portfolio, making the stock its 12th biggest holding. First Light Asset Management LLC owned approximately 8.61% of Health Catalyst worth $37,055,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Impax Asset Management Group plc increased its stake in Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock valued at $19,442,000 after buying an additional 195,525 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company's stock valued at $11,749,000 after acquiring an additional 66,896 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Health Catalyst during the fourth quarter worth about $2,044,000. Intech Investment Management LLC boosted its position in Health Catalyst by 59.7% during the fourth quarter. Intech Investment Management LLC now owns 28,386 shares of the company's stock valued at $201,000 after purchasing an additional 10,611 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Health Catalyst during the fourth quarter valued at approximately $110,000. Institutional investors own 85.00% of the company's stock.

Insider Buying and Selling

In related news, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total transaction of $62,912.85. Following the sale, the general counsel now owns 160,437 shares in the company, valued at approximately $729,988.35. This trade represents a 7.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Daniel Lesueur sold 5,209 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $5.76, for a total transaction of $30,003.84. Following the transaction, the chief operating officer now owns 86,044 shares of the company's stock, valued at approximately $495,613.44. This represents a 5.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,588 shares of company stock worth $225,906. Company insiders own 2.50% of the company's stock.

Health Catalyst Price Performance

Health Catalyst stock traded up $0.04 during mid-day trading on Thursday, reaching $3.99. 308,256 shares of the company were exchanged, compared to its average volume of 607,380. The firm has a market cap of $280.14 million, a PE ratio of -2.96 and a beta of 1.43. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company has a fifty day simple moving average of $4.22 and a 200-day simple moving average of $6.15. Health Catalyst, Inc. has a 12 month low of $3.56 and a 12 month high of $9.24.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HCAT. Canaccord Genuity Group dropped their price objective on Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada cut their price target on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research note on Thursday, February 27th. Evercore ISI lowered shares of Health Catalyst from an "outperform" rating to an "inline" rating in a research note on Wednesday, April 9th. Piper Sandler dropped their price objective on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 11th. Finally, Stephens cut their target price on shares of Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Thursday, March 6th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.05.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.